Fior Markets launched a study titled Antibiotics Market by Action (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, Others),Drug Class,Spectrum of Activity, Route of Administration, Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2019 to 2026”.

The global antibiotics market is expected to grow from USD 46.71 Billion in 2018 to USD 67.25 Billion by 2026 at a CAGR of 4.7% during the forecast period 2019-2026.Rising incidences of infectious diseases,development of better and improved products, and increasing collaborative development efforts are the factors boosting the demand of the antibiotics market.


RNA synthesis inhibitors segment is growing with the highest CAGR of 6.1% in the forecast period

The action segment is segmented into cell wall synthesis inhibitors, protein synthesis inhibitors, DNA synthesis inhibitors, RNA synthesis inhibitors and mycolic acid inhibitors. RNA synthesis inhibitors segment is growing with the highest CAGR in the forecast period. Adoption of several antiviral drugs inhibiting transcription and reverse transcription process are expected to promote the growth of the market.

The other antibiotics segment is anticipated to expand at the highest CAGR of 7.6% during the forecast year

The drug class segment is segmented into Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides and other. The other antibiotics segment is anticipated to expand at the highest CAGR during the forecast year. The other antibiotics segment comprises of tetracyclines, imidazoles, lincosamides, and monoclonal antibodies. The development of monoclonal antibodies for individuals that have developed antibiotic-resistance is a vital component for the growth of this segment.

The broad-spectrum antibiotic segment is dominating the market with the highest share of 59.90% in 2018

The spectrum of activitysegment is segmented into broad-spectrum antibiotic and narrow-spectrum antibiotic. The broad-spectrum antibiotic segment has dominated the market with the highest share in 2018. Broad-spectrum antibiotics act against a wide range of diseases, which in turn helps to combat antimicrobial resistance.

Regional Segmentation Analysis:

The market is analysed on the basis of five regions namely North America, Europe, Asia Pacific, South America, and Middle East and Africa. The North Americais dominating the market with the highest share of 41.20% in 2018owing to an increased use of antibiotics. In addition, there is a rise in per capita health expenditure in the country, which is expected to increase over the forecast period, due to decrease in the unemployment rate.

Antibiotics are group of medicines utilized in the treatment of contaminations brought about by germs, bacteria and certain parasites by restraining the development of microorganisms or killing them. Advancement of better and improved products has stimulated the growth and rising rates of infectious sicknesses are the factor adding to the market extension. The expanding cooperative improvement endeavor is additionally driving the development of the market.But uncertain regulatory policies may pose a major threat to the product. Nonetheless, evolution of advanced molecules and novel combination therapies to treat antibiotic-resistant microbial infections is probably going to spur market growth in coming years.

Access full report with TOC at:

Competitive Analysis:

The major players of the market include Pfizer, Inc; Janssen Pharmaceuticals; Abbott laboratories; GlaxoSmithKline plc; Sanofi S.A.; Novartis AG; Bayer AG; Bristol Myers Squibb Company; Eli Lilly & Company, and Astellas Pharma, Inc, Allergan Plc, F.Hoffmann-La Roche Ltd, Merck & Co. Inc., Mylan N.V., Sanofi, Teva Pharmaceutical Industries Ltd,Aurobindo Pharma, Lupin Pharmaceuticals, Sun Pharmaceutical, Shionogi, among many others.The companies are adopting strategies such as product innovations, mergers & acquisitions, recent developments, joint venture, collaborations, and partnership to maintain their presence in the global alpha-amylase baking enzyme market. For instance, in 2016, Pfizer entered into an agreement with AstraZeneca to acquire the development and commercialization rights to its late-stage small molecule anti-infective business, mainly outside U.S.

Customization of the Report:This report can be customized to meet the client’s requirements. Please connect with our sales team (, who will ensure that you get a report that suits your needs.